Short communication · 20 May 2016
Conference abstractPublished 5 Dec 2016
Differential binding force: A new physicochemical parameter for drug design
University of Houston, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The optimization of drug structures has conventionally used the binding constant, which corresponds to the Gibbs free energy, as the physicochemical parameter to quantitatively measure the binding efficiency. Recent studies have questioned whether this is the best criterion; enthalpy instead has been considered an alternative parameter, supported by several drugdeveloping paths. However, it remains difficult to experimentally obtain enthalpy that is specific to the drug binding process because of the limitations of micro-calorimetry. We propose to use the differential binding force (DBF) as a new parameter to quantify the binding efficiency and stability of drug candidates. DBF is defined as the difference between the binding forces of ligand-receptor pairs with and without drug interactions. The binding forces are determined by force-induced remnant magnetization spectroscopy (FIRMS). The experimental scheme is that one of the ligand-receptor pairs is immobilized on the surface, while the other is labeled with magnetic beads. The magnetic signal is measured by an atomic magnetometer as a function of an external mechanical force. The binding force is given as the external force at which there is a decrease in the magnetic signal due to the dissociation of the ligand-receptor bonds. Because of the high force resolution and detection efficiency, DBF of drugs can be obtained more precisely than any other techniques. This method has been applied for various drug-DNA systems and revealed an unusual mutual selectivity between drug chirality and DNA sequence. Future applications and further technological development will be discussed.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Research article · 26 Feb 2020
Design, Synthesis, Cytotoxicity, Physicochemical and In Vivo Studies of New Thalidomide Dithiocarbamate Analogs as Anticancer
Mini review · 20 Dec 2021
Ways to deal with Phase 1 Clinical Trial Design Focused on Safety, Efficiency and Selected Patient Populations: A Report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee
Review article · 2020
Study of some of Novel Selena-Diazole Derivative activities on Hematological Parameters, Differentiate lymphocytes cells in addition to thyroid hormones levels in Female Rats (One of the series of studies on the impact of the new compound)
Conference abstract · 2022
Prondicic acid (2-oxetanon-3, 4-diacetic acid): discovery, in silico drug design, syhtehic route, and importance as a highly potent enzyme inhibitor and the possible uses as a funtional group attached to dihalogenated anti-cancer drug compounds to increase efficacy and enzymatic target binding for more specific tumour targeting
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Shoujun Xu”
